首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   175586篇
  免费   7251篇
  国内免费   319篇
耳鼻咽喉   3114篇
儿科学   6664篇
妇产科学   4463篇
基础医学   24519篇
口腔科学   5113篇
临床医学   13286篇
内科学   31993篇
皮肤病学   4806篇
神经病学   16105篇
特种医学   8979篇
外国民族医学   24篇
外科学   29403篇
综合类   1119篇
一般理论   39篇
预防医学   8344篇
眼科学   4707篇
药学   12067篇
中国医学   353篇
肿瘤学   8058篇
  2023年   823篇
  2021年   1352篇
  2020年   1240篇
  2019年   1442篇
  2018年   3076篇
  2017年   2528篇
  2016年   3537篇
  2015年   3899篇
  2014年   4124篇
  2013年   5930篇
  2012年   8568篇
  2011年   8001篇
  2010年   4886篇
  2009年   3860篇
  2008年   7831篇
  2007年   8636篇
  2006年   8737篇
  2005年   9096篇
  2004年   8633篇
  2003年   8511篇
  2002年   8412篇
  2001年   6298篇
  2000年   6358篇
  1999年   5513篇
  1998年   1664篇
  1997年   1377篇
  1996年   1069篇
  1995年   871篇
  1994年   825篇
  1992年   2468篇
  1991年   2384篇
  1990年   2336篇
  1989年   2189篇
  1988年   1911篇
  1987年   1883篇
  1986年   1762篇
  1985年   1683篇
  1984年   1338篇
  1983年   1063篇
  1979年   1422篇
  1978年   1031篇
  1977年   881篇
  1975年   1103篇
  1974年   1150篇
  1973年   1043篇
  1972年   1041篇
  1971年   1008篇
  1970年   911篇
  1969年   838篇
  1968年   812篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Immunologic Research - Hyper immunoglobulin M (HIGM) syndrome is a rare disorder of the immune system with impaired antibody functions. The clinical picture of the patients varies according to the...  相似文献   
2.
Clinical Rheumatology - Aimed to evaluate the time elapsed between the onset of early symptoms and the diagnosis of fibromyalgia syndrome (FMS), the delays in diagnosis and frequent physician...  相似文献   
3.
4.
Münch  F.  Purbojo  A.  Wenzel  F.  Kohl  M.  Dittrich  S.  Rauh  M.  Zimmermann  R.  Kwapil  N. 《Der Anaesthesist》2022,71(11):882-892
Die Anaesthesiologie - Die Transfusion von Erythrozytenkonzentraten (EK) ist mit verschiedenen Nebenwirkungen assoziiert, die u. a. durch Lagerungsschäden an Erythrozyten hervorgerufen...  相似文献   
5.
6.
Intratumor heterogeneity is a main cause of the dismal prognosis of glioblastoma (GBM). Yet, there remains a lack of a uniform assessment of the degree of heterogeneity. With a multiscale approach, we addressed the hypothesis that intratumor heterogeneity exists on different levels comprising traditional regional analyses, but also innovative methods including computer-assisted analysis of tumor morphology combined with epigenomic data. With this aim, 157 biopsies of 37 patients with therapy-naive IDH-wildtype GBM were analyzed regarding the intratumor variance of protein expression of glial marker GFAP, microglia marker Iba1 and proliferation marker Mib1. Hematoxylin and eosin stained slides were evaluated for tumor vascularization. For the estimation of pixel intensity and nuclear profiling, automated analysis was used. Additionally, DNA methylation profiling was conducted separately for the single biopsies. Scoring systems were established to integrate several parameters into one score for the four examined modalities of heterogeneity (regional, cellular, pixel-level and epigenomic). As a result, we could show that heterogeneity was detected in all four modalities. Furthermore, for the regional, cellular and epigenomic level, we confirmed the results of earlier studies stating that a higher degree of heterogeneity is associated with poorer overall survival. To integrate all modalities into one score, we designed a predictor of longer survival, which showed a highly significant separation regarding the OS. In conclusion, multiscale intratumor heterogeneity exists in glioblastoma and its degree has an impact on overall survival. In future studies, the implementation of a broadly feasible heterogeneity index should be considered.  相似文献   
7.
8.
9.
IntroductionLymphedema is the most important complication seen after breast cancer surgery. The study aimed to evaluate pain, shoulder-arm complex function, and scapular function in women who developed lymphedema after breast cancer surgery and to compare these with women without lymphedema.Materials and MethodsFifty women with lymphedema (age, 54.34 ± 9.08 years; body mass index, 30.10 ± 4.03 kg/cm2) and 57 women without lymphedema (age, 53.68 ± 9.41 years; body mass index, 29.0 ± 5.44 kg/cm2) after unilateral surgery for breast cancer were included. Clinical and demographic information was noted. The severity of lymphedema with perimeter measurements (Frustum model), level of heaviness discomfort sensation with a visual analog scale, pain threshold with a digital algometer, shoulder-arm complex functionality with the Disabilities of the Arm, Shoulder, Hand Problems Survey (DASH), and scapular function with observational scapular dyskinesia and lateral scapular sliding tests were assessed. The t test, χ2 test, and Mann-Whitney U test were used for analyses.ResultsThe follow-up duration after the surgery was 4.24 ± 2.97 years and 3.19 ± 1.76 years, and the upper extremity volume was 2106.65 ± 510.82 cm3 and 1725.92 ± 342.49 cm³ in the lymphedema group and in the no-lymphedema group, respectively. In the lymphedema group, arm-heaviness discomfort, pain threshold levels in the trapezius and deltoid muscles, and DASH scores were worse (P < .05). The rate of scapular dyskinesia (70.0%) and type 2 scapula (32%) in the surgical side was higher in patients with lymphedema.ConclusionThe pain pressure threshold in the trapezius and deltoid muscles, heaviness sensation level, and inadequate upper extremity function are significantly higher in patients with lymphedema, and the scapular dyskinesia rate was higher.  相似文献   
10.
There have been a number of investigations of the efficacy and safety of etanercept. This study was performed to obtain long-term drug survival data (ie, time to drug discontinuation) for etanercept, and the reasons for its discontinuation. The study population consisted of patients with psoriatic arthritis and psoriasis followed up by our clinic, registered in the Turkish Psoriasis Registry (PSR-TR) and treated with etanercept for at least 4 weeks between January 1, 2005, and January 31, 2020. The efficacy of etanercept was evaluated in terms of the Psoriasis Area and Severity Index (PASI) 75, PASI 90 and PASI 100 response rates at 12, 24, 36, and 48 weeks, and annually thereafter. The behaviors of the patients with respect to the use of etanercept, and the outcomes of those who continued to use it during the COVID-19 pandemic, were also investigated.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号